{"id":70523,"date":"2026-07-23T22:13:42","date_gmt":"2026-07-23T14:13:42","guid":{"rendered":"https:\/\/flcube.com\/?p=70523"},"modified":"2026-07-23T22:13:43","modified_gmt":"2026-07-23T14:13:43","slug":"pegbio-launches-commercial-prescriptions-for-paidakang-glp-1ra-in-china-triggers-milestone-payments","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70523","title":{"rendered":"PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>PegBio Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2565:HKG\">HKG: 2565<\/a>) announced the successful issuance of the <strong>first batch of commercial prescriptions<\/strong> for its <strong>Category 1 innovative drug, Paidakang (Visepegenatide injection)<\/strong>, across China. The long-acting <strong>glucagon-like peptide-1 receptor agonist (GLP-1RA)<\/strong> has been approved by the <strong>National Medical Products Administration (NMPA)<\/strong> for treating <strong>type 2 diabetes in adults<\/strong>, marking PegBio&#8217;s entry into the competitive $4.8 billion Chinese diabetes therapeutics market.<\/p>\n\n\n\n<h2 id=\"h-commercial-launch-milestone\" class=\"wp-block-heading\">Commercial Launch Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>PegBio Co., Ltd. (HKG: 2565)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Paidakang (Visepegenatide injection)<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Category 1 innovative drug (GLP-1RA weekly formulation)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Type 2 diabetes in adults<\/td><\/tr><tr><td><strong>Regulatory Approval<\/strong><\/td><td>NMPA marketing authorization<\/td><\/tr><tr><td><strong>Commercial Status<\/strong><\/td><td>First prescriptions issued nationwide<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-partnership-amp-financial-framework\" class=\"wp-block-heading\">Partnership &amp; Financial Framework<\/h2>\n\n\n\n<h3 id=\"h-exclusive-commercialization-agreement\" class=\"wp-block-heading\">Exclusive Commercialization Agreement<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Partner<\/strong>: Shanghai Tenry Pharmaceutical Co., Ltd. (&#8220;Tenry Pharma&#8221;)<\/li>\n\n\n\n<li><strong>Territory<\/strong>: Mainland China exclusive rights<\/li>\n\n\n\n<li><strong>Product<\/strong>: Paidakang (referred to as &#8220;Pidacang&#8221; in agreement)<\/li>\n\n\n\n<li><strong>Development<\/strong>: Independently developed by PegBio as long-acting weekly GLP-1RA<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-milestone-payment-structure\" class=\"wp-block-heading\">Milestone Payment Structure<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First Milestone<\/strong>: <strong>HKD 61 million<\/strong> (already received upon agreement execution)<\/li>\n\n\n\n<li><strong>Second Milestone<\/strong>: <strong>HKD 49 million<\/strong> (triggered by nationwide commercial prescription rollout)<\/li>\n\n\n\n<li><strong>Total Initial Payments<\/strong>: <strong>HKD 110 million<\/strong> (~USD 14.1 million) realized upon commercial launch<\/li>\n\n\n\n<li><strong>Additional Consideration<\/strong>: Potential sales-based royalties and future development milestones<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-drug-profile-amp-market-positioning\" class=\"wp-block-heading\">Drug Profile &amp; Market Positioning<\/h2>\n\n\n\n<h3 id=\"h-therapeutic-characteristics\" class=\"wp-block-heading\">Therapeutic Characteristics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Class<\/strong>: Long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA)<\/li>\n\n\n\n<li><strong>Dosing Regimen<\/strong>: Weekly subcutaneous injection<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Enhances glucose-dependent insulin secretion, suppresses glucagon release, and promotes satiety<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: Independently developed Chinese innovation with potential dosing convenience advantages<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-landscape\" class=\"wp-block-heading\">Competitive Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Context<\/strong>: Chinese GLP-1RA market growing at 25% CAGR, dominated by imported products<\/li>\n\n\n\n<li><strong>Local Innovation<\/strong>: Represents domestic alternative to multinational GLP-1 therapies<\/li>\n\n\n\n<li><strong>Patient Access<\/strong>: Weekly dosing improves adherence compared to daily alternatives<\/li>\n\n\n\n<li><strong>Commercial Infrastructure<\/strong>: Leveraging Tenry Pharma&#8217;s established diabetes commercial network<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Acceleration<\/strong>: Immediate milestone payments provide non-dilutive capital for pipeline advancement<\/li>\n\n\n\n<li><strong>Market Validation<\/strong>: Successful commercial launch demonstrates physician acceptance and payer support<\/li>\n\n\n\n<li><strong>Partnership Model<\/strong>: Validates PegBio&#8217;s strategy of leveraging specialized commercial partners for optimal market penetration<\/li>\n\n\n\n<li><strong>Pipeline Catalyst<\/strong>: Commercial success may enhance valuation of PegBio&#8217;s broader metabolic disease portfolio<\/li>\n\n\n\n<li><strong>Export Potential<\/strong>: Domestic success could support international regulatory filings and partnership opportunities<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercial performance, partnership execution, and financial expectations. Actual results may differ due to risks including market adoption rates, competitive dynamics, reimbursement decisions, and partnership implementation.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072200735_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026072200735_c.\"><\/object><a id=\"wp-block-file--media-bbc30970-fc79-4f9f-9f61-8c2e5a67d70f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072200735_c.pdf\">2026072200735_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072200735_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-bbc30970-fc79-4f9f-9f61-8c2e5a67d70f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PegBio Co., Ltd. (HKG: 2565) announced the successful issuance of the first batch of commercial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":70525,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[4078,4361,40,2105],"class_list":["post-70523","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hkg-2565","tag-hot-targets","tag-market-launch","tag-pegbio"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"PegBio Co., Ltd. (HKG: 2565) announced the successful issuance of the first batch of commercial prescriptions for its Category 1 innovative drug, Paidakang (Visepegenatide injection), across China. The long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) has been approved by the National Medical Products Administration (NMPA) for treating type 2 diabetes in adults, marking PegBio&#039;s entry into the competitive $4.8 billion Chinese diabetes therapeutics market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70523\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments\" \/>\n<meta property=\"og:description\" content=\"PegBio Co., Ltd. (HKG: 2565) announced the successful issuance of the first batch of commercial prescriptions for its Category 1 innovative drug, Paidakang (Visepegenatide injection), across China. The long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) has been approved by the National Medical Products Administration (NMPA) for treating type 2 diabetes in adults, marking PegBio&#039;s entry into the competitive $4.8 billion Chinese diabetes therapeutics market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70523\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-23T14:13:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-23T14:13:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2304.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70523#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70523\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments\",\"datePublished\":\"2026-07-23T14:13:42+00:00\",\"dateModified\":\"2026-07-23T14:13:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70523\"},\"wordCount\":383,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70523#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2304.webp\",\"keywords\":[\"HKG: 2565\",\"Hot targets\",\"Market launch\",\"PegBio\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70523#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70523\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70523\",\"name\":\"PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70523#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70523#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2304.webp\",\"datePublished\":\"2026-07-23T14:13:42+00:00\",\"dateModified\":\"2026-07-23T14:13:43+00:00\",\"description\":\"PegBio Co., Ltd. (HKG: 2565) announced the successful issuance of the first batch of commercial prescriptions for its Category 1 innovative drug, Paidakang (Visepegenatide injection), across China. The long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) has been approved by the National Medical Products Administration (NMPA) for treating type 2 diabetes in adults, marking PegBio's entry into the competitive $4.8 billion Chinese diabetes therapeutics market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70523#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70523\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70523#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2304.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2304.webp\",\"width\":1080,\"height\":608,\"caption\":\"PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70523#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments - Insight, China&#039;s Pharmaceutical Industry","description":"PegBio Co., Ltd. (HKG: 2565) announced the successful issuance of the first batch of commercial prescriptions for its Category 1 innovative drug, Paidakang (Visepegenatide injection), across China. The long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) has been approved by the National Medical Products Administration (NMPA) for treating type 2 diabetes in adults, marking PegBio's entry into the competitive $4.8 billion Chinese diabetes therapeutics market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70523","og_locale":"en_US","og_type":"article","og_title":"PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments","og_description":"PegBio Co., Ltd. (HKG: 2565) announced the successful issuance of the first batch of commercial prescriptions for its Category 1 innovative drug, Paidakang (Visepegenatide injection), across China. The long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) has been approved by the National Medical Products Administration (NMPA) for treating type 2 diabetes in adults, marking PegBio's entry into the competitive $4.8 billion Chinese diabetes therapeutics market.","og_url":"https:\/\/flcube.com\/?p=70523","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-23T14:13:42+00:00","article_modified_time":"2026-07-23T14:13:43+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2304.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70523#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70523"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments","datePublished":"2026-07-23T14:13:42+00:00","dateModified":"2026-07-23T14:13:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70523"},"wordCount":383,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=70523#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2304.webp","keywords":["HKG: 2565","Hot targets","Market launch","PegBio"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70523#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70523","url":"https:\/\/flcube.com\/?p=70523","name":"PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=70523#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=70523#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2304.webp","datePublished":"2026-07-23T14:13:42+00:00","dateModified":"2026-07-23T14:13:43+00:00","description":"PegBio Co., Ltd. (HKG: 2565) announced the successful issuance of the first batch of commercial prescriptions for its Category 1 innovative drug, Paidakang (Visepegenatide injection), across China. The long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) has been approved by the National Medical Products Administration (NMPA) for treating type 2 diabetes in adults, marking PegBio's entry into the competitive $4.8 billion Chinese diabetes therapeutics market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70523#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70523"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=70523#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2304.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2304.webp","width":1080,"height":608,"caption":"PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70523#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2304.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70523","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70523"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70523\/revisions"}],"predecessor-version":[{"id":70526,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70523\/revisions\/70526"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/70525"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70523"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70523"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70523"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}